Physician profile
Gary Steven Feldman
NPI 1891715009
$4,200.18
in general payments reported to CMS, 2019-2025
16 companies · $1,893 in 2025
The $1,893 reported for 2025 was more than what 82% of Sleep Medicine (Family Medicine) providers received nationally (typical 2025 total: $557).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $198 · 2020: $21.49 · 2021: $1,127 · 2022: $257 · 2023: $134 · 2024: $570 · 2025: $1,893.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,460 · Travel and Lodging: $993 · Education: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,459.52 |
| Travel and Lodging | $992.91 |
| Education | $144.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $1,271.51 | 2025 | Bpn14770 |
| Janssen Scientific Affairs, LLC | $1,000.00 | 2021 | |
| Jazz Pharmaceuticals INC. | $625.87 | 2019-2025 | Xywav |
| Inspire Medical Systems, INC. | $208.90 | 2024-2025 | Inspire |
| Harmony Biosciences LLC | $206.20 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $198.36 | 2021-2025 | Qelbree, Qelbree |
| Boston Scientific Corporation | $150.00 | 2025 | Wavewriter Alpha Prime 16 |
| Corium, LLC | $114.15 | 2023-2024 | Azstarys |
| Avadel Cns Pharmaceuticals, LLC | $113.39 | 2025 | Lumryz |
| Noctrix Health, INC. | $94.63 | 2024 | Nidra |
| Axsome Therapeutics, INC. | $50.27 | 2023-2025 | Sunosi |
| Idorsia Pharmaceuticals US INC | $41.20 | 2023 | Quviviq |
| Collegium Pharmaceutical, INC. | $38.46 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $34.68 | 2022 | |
| Mirum Pharmaceuticals, INC. | $31.47 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $21.09 | 2025 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Feldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.